3176 results for «358»
3176 results
What is new in atrioventricular valves?
19 May 2025 – From EuroPCR 2025
Discover the latest advancements in atrioventricular valve interventions, including innovative transcatheter repair technologies and first-in-human experiences with novel devices.
Nurses and allied professionals abstracts session
20 May 2025 – From EuroPCR 2025
Highlight the pivotal role of nurses and allied health professionals in interventional cardiology through a series of abstracts addressing radial haemostasis, TAVI nursing programs, early mobilization, radiation protection, and physiologist-led intracoronary thermodilution assessments.
New solutions for old problems
19 May 2025 – From EuroPCR 2025
Discover new solutions addressing persistent cardiovascular challenges, including novel diagnostic systems, vascular closure devices, specialized transcatheter closure technologies, and innovative stent-graft systems.
Complex PCI in calcific coronary artery disease - LIVE Case
20 May 2025 – From EuroPCR 2025
A 76-year-old male patient presented with a significant history of coronary artery disease: CABG with LIMA/LAD and RIMA/OM (1996), RCA PCI with BVS (2016), OM PCI (2017), RIMA occlusion and OM retenosis treated with DCB (2022) with preserved LV. He was admitted for pre-operative evaluation prior...
Mitral hotline: new devices
20 May 2025 – From EuroPCR 2025
Stay updated on emerging devices in mitral valve repair and replacement with this session covering novel technologies including transcatheter edge-to-edge repair (TEER), posterior leaflet restoration, transfemoral mitral annuloplasty, and a first-in-human transseptal TMVR system. Clinical trial data and early feasibility experiences provide valuable insights into advancing...
Stable CAD and multivessel disease
20 May 2025 – From EuroPCR 2025
This session delves into the management of stable coronary artery disease (CAD) with multivessel involvement. Learn how clinical and procedural factors influence revascularisation strategies, debate the merits of complete revascularisation, and explore decision-making processes between anatomical and functional approaches through illustrative cases and expert analysis.
Managing TAVI complications
20 May 2025 – From EuroPCR 2025
Gain expertise in managing TAVI complications including strategic retrieval of embolized valves, handling unexpected additional valve usage, managing left ventricle suicide phenomenon, and integrating coronary intervention tools during structural heart procedures, supported by instructive case series.
From crossroads to crossovers: cracking the left main code
20 May 2025 – From EuroPCR 2025
Navigate complex scenarios in left main coronary artery interventions with this session focusing on protected left main and multivessel disease, IVUS-guided PCI, stent optimization, and in-stent restenosis management. Real-world cases from Azerbaijan, Moldova, and Iraq provide collaborative insights and innovative strategies for challenging coronary anatomy.
LAA closure and anthrombotic therapies
21 May 2025 – From EuroPCR 2025
Explore contemporary evidence on left atrial appendage (LAA) closure and associated antithrombotic therapies. This session covers strategies for antithrombotic de-escalation, efficacy and safety in patients with anticoagulation contraindications, breakthrough stroke etiology, and anatomical considerations in high-risk atrial fibrillation patients undergoing ablation.
Updates in transcatheter MVR
21 May 2025 – From EuroPCR 2025
This session provides a detailed overview of recent advances in transcatheter mitral valve replacement (TMVR). Examine outcomes from next-generation transcatheter heart valves, long-term clinical data from mitral valve-in-valve and valve-in-ring procedures, and explore innovative approaches including transseptal MVR with insights from global studies.
Coronary scaffolds: new developments and applications
21 May 2025 – From EuroPCR 2025
Stay informed on advancements in coronary scaffolds with this session reviewing new developments and applications. Topics include comparative performance of magnesium-based bioresorbable stents, long-term clinical outcomes from the BIOMAG-I and FANTOM BRS studies, and real-world experiences with next-generation thin-strut scaffolds.
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...
Author
Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...
Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.
Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.
Author
